p38α MAPK Inhibitor Selection for Tau-Negative DLB Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no approved therapies to effectively treat Dementia with Lewy Bodies (DLB) that do not involve substantial tau pathology, and existing treatments for DLB often fail to address synaptic dysfunction and neuronal loss.
Innovation Solution
Administering a selective p38α mitogen-activated protein kinase (MAPK) inhibitor, such as neflamapimod, to patients with DLB who have no substantial tau pathology, characterized by specific biomarkers like low levels of phosphorylated tau in plasma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing DLB treatments are used, then some symptomatic improvement may be achieved, but they fail to address synaptic dysfunction and neuronal loss effectively
Solution Approach 1:
The patent changes the therapeutic parameter by targeting p38α MAPK specifically, which is different from conventional DLB treatments. This parameter change allows the treatment to address synaptic dysfunction and neuronal loss mechanisms that were not targeted before, thereby improving reliability while reducing harmful effects.
Solution Approach 2:
The patent extracts the p38α MAPK inhibition mechanism from general DLB treatment approaches and applies it specifically to patients without substantial tau pathology. This extraction allows targeted treatment that addresses synaptic and neuronal issues without the side effects of broader treatments.
2Reliability
If tau pathology is present in DLB patients, then Alzheimer's disease pathology is associated, but selective p38α MAPK inhibitor treatment is most effective in patients without substantial tau pathology
Solution Approach 1:
The patent applies local quality by tailoring the treatment to a specific subset of DLB patients - those without substantial tau pathology. This localized approach ensures high treatment reliability for the target population while acknowledging that the treatment may not be as effective for patients with tau pathology, thus managing adaptability appropriately.
3Adaptability or versatility
If no approved therapies exist for DLB without tau pathology, then treatment options are limited, but neflamapimod provides effective treatment for this specific population
Solution Approach 1:
The patent segments the DLB patient population into those with and without substantial tau pathology, and provides a specific treatment (neflamapimod) for the segment without tau pathology. This segmentation creates a tailored treatment option that improves both availability and effectiveness for the specific patient group.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Neflamapimod effectively treats DLB symptoms, reverses synaptic dysfunction, and inhibits neuronal loss in patients without substantial tau pathology, improving cognitive and motor functions.
Implementation Method 1
administration of a selective p38 α MAPK inhibitor, neflamapimod, is effective to treatment a select patient population that has Dementia with Lewy Bodies (DLB) but no substantial tau pathology
Data Source
AI summary
The present invention provides methods and compositions for the treatment of subjects that have Dementia with Lewy Bodies (DLB) but have no substantial tau pathology. Subjects with DLB that have no substantial tau pathology are shown to be particularly responsive to treatment with a selective p38α mitogen activated protein kinase (MAPK) inhibitor compared to subjects with DLB that have substantial tau pathology.